PTC Therapeutics (NASDAQ:PTCT) CAO Christine Marie Utter Sells 1,034 Shares

PTC Therapeutics, Inc. (NASDAQ:PTCT) CAO Christine Marie Utter sold 1,034 shares of the company’s stock in a transaction on Thursday, January 8th. The stock was sold at an average price of $76.45, for a total value of $79,049.30. Following the sale, the chief accounting officer owned 72,693 shares of the company’s stock, valued at approximately $5,557,379.85. This represents a 1.40% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Christine Marie Utter also recently made the following trade(s):

• On Wednesday, January 7th, Christine Marie Utter sold 1,235 shares of PTC Therapeutics stock. The shares were sold at an average price of $77.45, for a total transaction of $95,650.75.
• On Tuesday, January 6th, Christine Marie Utter sold 1,381 shares of PTC Therapeutics stock. The shares were sold at an average price of $76.95, for a total transaction of $106,267.95.

PTC Therapeutics Stock Performance

NASDAQ PTCT opened at $77.59 on Tuesday. PTC Therapeutics, Inc. has a fifty-two week low of $35.95 and a fifty-two week high of $87.50. The stock has a market cap of $6.23 billion, a PE ratio of 9.06 and a beta of 0.49. The firm’s fifty day moving average price is $76.81 and its two-hundred day moving average price is $63.11.

PTC Therapeutics (NASDAQ:PTCT) last issued its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.20 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.19) by $1.39. The business had revenue of $211.01 million during the quarter, compared to analysts’ expectations of $177.42 million. PTC Therapeutics had a negative return on equity of 194.11% and a net margin of 42.25%.The business’s revenue for the quarter was up 7.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($1.39) EPS. As a group, sell-side analysts predict that PTC Therapeutics, Inc. will post -4.52 earnings per share for the current fiscal year.

Institutional Investors Weigh In On PTC Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Ameritas Investment Partners Inc. increased its position in shares of PTC Therapeutics by 3.0% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 7,936 shares of the biopharmaceutical company’s stock valued at $388,000 after purchasing an additional 231 shares during the last quarter. Smartleaf Asset Management LLC lifted its holdings in PTC Therapeutics by 101.3% during the third quarter. Smartleaf Asset Management LLC now owns 469 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 236 shares during the last quarter. Optiver Holding B.V. boosted its position in PTC Therapeutics by 96.5% during the third quarter. Optiver Holding B.V. now owns 507 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 249 shares during the period. PNC Financial Services Group Inc. raised its holdings in PTC Therapeutics by 42.1% during the 2nd quarter. PNC Financial Services Group Inc. now owns 995 shares of the biopharmaceutical company’s stock valued at $49,000 after acquiring an additional 295 shares during the period. Finally, IFP Advisors Inc lifted its holdings in PTC Therapeutics by 68.1% during the 3rd quarter. IFP Advisors Inc now owns 765 shares of the biopharmaceutical company’s stock worth $47,000 after purchasing an additional 310 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. The Goldman Sachs Group lifted their price target on shares of PTC Therapeutics from $44.00 to $50.00 and gave the stock a “sell” rating in a report on Wednesday, November 5th. Wall Street Zen raised PTC Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, January 3rd. Weiss Ratings reiterated a “hold (c)” rating on shares of PTC Therapeutics in a research report on Monday, December 29th. Royal Bank Of Canada cut shares of PTC Therapeutics from an “outperform” rating to a “sector perform” rating and increased their price objective for the stock from $82.00 to $91.00 in a research report on Monday, December 1st. Finally, Citigroup increased their price target on PTC Therapeutics from $50.00 to $75.00 and gave the stock a “neutral” rating in a report on Wednesday, November 5th. Nine analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $77.27.

Trending Headlines about PTC Therapeutics

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: PTC provided a detailed update at the J.P. Morgan conference saying Sephience™ (sepiapterin) continues to scale — unaudited Q4 global Sephience revenue of $92.5M, unaudited 2025 total product & royalty revenue of ~ $823M (above guidance), 2026 product revenue guidance of $700–800M (implying ~19–36% YoY growth), and cash of ~$1.94B. These results and the 2026 guidance are the main bullish catalysts for the stock today. PTC Therapeutics Provides Update at J.P. Morgan Annual Healthcare Conference
• Positive Sentiment: PTC presented at the 44th Annual J.P. Morgan Healthcare Conference (transcript available), reinforcing commercial execution and management commentary that supports the guidance and growth story. Conference Transcript
• Neutral Sentiment: Reported short interest data shows 0 shares (appears to be a data anomaly / NaN change) and a 0.0 days-to-cover — likely not meaningful to trading given the company’s volume and recent volatility. (Source: market data entry)
• Negative Sentiment: Multiple insiders disclosed open‑market sales between Jan 6–12 (CEO Matthew B. Klein, CFO Pierre Gravier, VP Mark Boulding, EVP/other officers including Eric Pauwels, Christine Utter, Lee Golden, Neil Almstead). Individual sales ranged from several dozen to several thousand shares; the CEO and other executives still retain large positions. Insider selling can create short‑term caution among investors even when shares are sold in open‑market transactions. Key filings/articles: CEO Form 4 (SEC). CEO Form 4 Eric Pauwels Form 4 (SEC). Pauwels Form 4 Media summary of CFO/CEO sales. Insider Selling Article

About PTC Therapeutics

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.